FDA Grants Fast Track Designation for Bepirovirsen for Chronic Hepatitis B
The investigational antisense oligonucleotide’s designation is based on data from the phase 2b trials B-Clear and B-Sure.
Source: hcplive.com
📰 Functional Cure News
Functional Cure News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Functional Cure. Real-time updates on events, politics, business and more.
Seraxis to Provide Oral Update on Its Pancreatic Organoid Candidate for Functional Cure of T1D at th
Dr. William Rust will give an oral presentation on Seraxis’ proprietary technology for the production of therapeutic pancreatic organoids from pancreas-derived stem cells, as well as review initial diabetes model data of functional cure of Type 1 Diabetes. Seraxis’ presentation, entitled “Stem-cell Derived Islets fo...
United States Ted Hibben William Rust Seraxis Inc Corporate Development European Association For The Study Of Diabetes
Source: pharmiweb.com
Bioxytran (OTCMKTS: BIXT) Peer-Review Published Showing Functional Cure for COVID-19
A new peer-reviewed medical journal article demonstrates a functional cure for COVID-19, influenza, and RSV. ProLectin-M also eliminates symptoms.
Chris Turnbull Michael Sheikh Sheikh Linkedin Bioxytran Inc Oral Galectin Inhibitor Controlled Trial
Source: microcapdaily.com
AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...
Source: prnewswire.com
AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...
Source: prnewswire.com
AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...
Source: prnewswire.com
Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a 'Functional Cure' for Diabetes | DNA RNA and Cells
Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a ‘Functional Cure’ for Diabetes
Source: pipelinereview.com
Brii Biosciences Provides Corporate Update and Reports Full Year 2021 Financial Results
/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio", "we" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for...
Hong Kong Zhi Hong Brii Bio Vir Biotechnology Inc Infections Program National Health Commission Of China
Source: prnewswire.com
Immunocore announces dosing of first patient with ImmTAV®
molecules and infectious diseases ImmTAV (Immune mobilising mTCR Against Virus) molecules are novel bispecific molecules that, like ImmTAC (Immune mobilising monoclonal TCRs Against Cancer) molecules, are designed to enable the immune system to recognize and eliminate virally infected cells. Immunocore aims to achieve sustained loss of circulating viral antigens and markers of viral replication after stopping medication for people living with chronic hepatitis B. This is known as “functional...
Debra Nielsen Fung Yuen Division Of Gastroenterology Hepatology Head Of Communications Exchange Commission On Immunocore Holdings Plc Nasdaq
Source: globenewswire.com